Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new screening method combining blood multi-gene methylation and fecal biomarkers to detect cancers throughout the digestive tract early. This observational study focuses on individuals aged 45 to 74 who are scheduled for digestive tract endoscopy. The goal is to establish a novel system that improves early diagnosis by measuring the sensitivity and specificity of these combined biomarkers. Participants will provide blood and stool samples before undergoing the endoscopic examination. The samples will be tested for specific gene methylation and fecal markers such as the immunochemical test and calprotectin. After the initial screening and endoscopic procedures with pathological confirmation, participants will be followed for five years to monitor outcomes and validate the screening method. Throughout the study, researchers will collect data on the accuracy of the combined biomarkers compared to endoscopy results, as well as track the detection rates of precancerous lesions and various digestive tract cancers over time. The study will also monitor any complications related to endoscopic screening, such as bleeding or infection. Participants will be involved in baseline sample collection, endoscopy, and long-term follow-up visits over five years.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a combined screening and follow-up management approach for gastrointestinal tumors. This study aims to explore and assess the feasibility and cost-effectiveness of screening for esophagus, stomach, and colorectal cancers in a population-based, multicenter setting. The trial includes participants aged 45 to 70 years and will observe outcomes over a 10-year follow-up period. Participants are divided into groups undergoing different screening methods. Group one receives gastroscopy, colonoscopy, fecal occult blood test FIT, Helicobacter pylori antigen test, RNF180 and SEPTIN9 gene methylation tests, along with an investigation of various risk factors such as past diseases, lifestyle habits, family cancer history, and reproductive status. Group two undergoes risk factor investigation, FIT, and Helicobacter pylori antigen stool test if positive, further gene methylation tests and possibly colonoscopy are conducted. Control groups matched by spouse or sibling undergo only risk factor investigations. During the study, participants provide information on medical history, lifestyle habits, and family cancer history. Screening tests including endoscopies, stool tests, and gene methylation analyses are performed as specified. Researchers will monitor the detection of cancer or precancerous lesions over 10 years, tracking health outcomes and the effectiveness of combined screening. Safety and adherence are observed throughout the follow-up.
Actively Recruiting
Phase 3 Randomized Trial Evaluating MI078 Capsules in Women with Postpartum Depression Aged 18 to 45
The trial investigates the use of MI078 capsules to treat postpartum depression in women aged 18 to 45 years. It is a multicenter, randomized, double-blind, placebo-controlled study aiming to assess the efficacy and safety of MI078 for this condition. Participants must have a diagnosis of major depressive disorder with onset during late pregnancy or early postpartum, and a certain level of depression severity as measured by the Hamilton Depression Rating Scale. Participants are randomly assigned to two groups one receiving MI078 capsules and the other receiving a matching placebo. The treatment is taken for 3 days during the treatment period. The study includes a screening phase lasting up to 14 days before treatment, a 4-day treatment period, and a follow-up period lasting until day 31 after treatment begins. During the study, participants will undergo clinical assessments including depression rating scales such as the HAM-D17 and other mood and anxiety scales. Researchers will monitor changes from baseline in depression scores and record safety information throughout the follow-up period. Participants are expected to comply with study requirements, lifestyle restrictions, and attend scheduled visits for evaluations over approximately one month.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a multicenter randomized controlled trial to evaluate a new screening approach for gastrointestinal cancers. This study compares an active screening strategy using a combined model of multi-target blood methylation, fecal FIT, and fecal calprotectin tests to routine observation. The goal is to determine if this combined model can reduce mortality from gastrointestinal cancers over five years and provide evidence for a better screening program. Participants are randomly assigned to one of two groups. The intervention group undergoes the combined testing model those with positive results receive standard gastrointestinal endoscopy immediately, while those with negative results continue with routine observation. The control group undergoes only routine observation and follow-up. All participants are followed prospectively for five years to gather information on the incidence and mortality of gastrointestinal cancers. Throughout the study, participants will be regularly contacted and their medical records reviewed to collect data on cancer diagnoses and deaths. Researchers will measure differences in gastrointestinal cancer mortality between the two groups after five years. Additional outcomes include cancer incidence, test accuracy, detection of early lesions, and endoscopy-related complications. The study provides a comprehensive evaluation of this screening strategy and its impact on public health over a long-term follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a translational observational study to describe clinical characteristics, treatment patterns, and biomarkers in asthma patients within the Chinese population. The study aims to identify phenotypes and endotypes linked to different outcomes, which may help develop personalized treatment strategies in the future. The study includes healthy individuals as well as patients with mild to severe asthma, including those experiencing asthma exacerbations. Participants are grouped into cohorts approximately 80 healthy individuals, 40 mild asthmatics using low-dose inhaled corticosteroids ICS-formoterol or low-dose ICS with as-needed short-acting beta-2 agonists SABA, 160 moderate to severe asthmatics on low or medium dose ICS-long acting beta-2 agonists LABA, or high-dose ICS alone or combined with LABA, and 75 asthmatics with protocol-defined exacerbations. The study involves detailed collection of clinical data, treatment information, and biomarker measurements. During the study, participants undergo assessments including lung function tests such as FEV1, Forced Vital Capacity FVC, and Maximal Mid Expiratory Flow MMEF, imaging by computed tomography CT scan, and evaluation of airway remodeling and gas trapping at baseline. Researchers will also summarize demographic, clinical, and biomarker data and analyze associations between biomarkers and clinical outcomes over time. The study will continue through 2026, with participants monitored for treatment patterns and biomarker changes.
Actively Recruiting
Researchers are evaluating the use of absorbable and moldable skull base support plates in patients undergoing extended endoscopic endonasal transsphenoidal surgery for sellar region tumors. The study aims to compare the incidence of cerebrospinal fluid CSF rhinorrhea within one month after surgery between patients receiving standard sellar floor repair combined with the support plate and those receiving standard repair alone. This phase II, randomized, controlled trial also assesses intracranial infection rates, surgery duration, hospital stay length, and safety, including nasal complications. Participants will be randomly assigned to one of two groups. The experimental group will receive a skull base repair that includes the use of a shaped and trimmed absorbable and moldable support plate placed during surgery, covered with nasal septal mucosa and stabilized with gelatin sponge. The control group will undergo the standard multi-layer sellar floor repair without the support plate but with similar packing and mucosal coverage. The trial follows a 11 parallel design and plans to enroll approximately 126 patients. During the study, participants will be monitored for CSF rhinorrhea and intracranial infections within the first month after surgery using clinical symptoms, imaging, and nasal endoscopy. Researchers will also record surgery duration and hospital stay length. Safety will be assessed by tracking treatment-related adverse events, especially nasal complications. Follow-up includes face-to-face visits for patients returning for reexamination and telephone follow-ups for those who cannot. Data will be analyzed using established statistical methods to evaluate the outcomes and safety over the study period.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a multi-center observational study to develop and assess the accuracy of fecal multi-marker panels for screening gastrointestinal cancers, specifically gastric and colorectal cancers. The study aims to evaluate the sensitivity and specificity of stool-based biomarker testing compared to baseline endoscopic screening. This research will help determine how well these stool tests can identify gastrointestinal cancers early. Participants scheduled for gastroscopy and colonoscopy will provide a stool sample before their endoscopic procedures. These samples will undergo qualitative and quantitative Fecal Immunochemical Tests FIT along with novel biomarker testing. After the initial endoscopic screening, participants will be followed for two years to monitor outcomes and assess the screening tests performance. During the study, participants will have stool samples collected before their endoscopy appointments. Data from these tests will be compared to the results of their endoscopic examinations conducted about two weeks later. Researchers will focus on measuring the sensitivity and specificity of the fecal biomarker tests for cancer screening. The two-year follow-up will provide additional information on the tests effectiveness and participants health outcomes throughout this period.
Actively Recruiting
Researchers are investigating the changes in circulating multigene methylation levels before and after treatment in patients with esophageal cancer. The study aims to see how these methylation changes relate to response rates measured by imaging and serum tumor markers. Secondary goals include examining how methylation patterns relate to progression-free survival, comparing methylation indices to traditional biomarkers, and exploring the use of methylation thresholds to guide therapy adjustments. Participants are grouped based on their treatment approach primary surgical treatment, surgery after neoadjuvant therapy, active surveillance after neoadjuvant therapy, or definitive chemoradiotherapy with or without immunotherapy. Each group undergoes multi-gene methylation testing through blood samples taken at specific intervals depending on the treatment stage, ranging from pre-treatment baselines to up to five years post-treatment. This allows for detailed monitoring of methylation changes over time. During the study, participants will also have regular tumor marker tests, imaging exams such as contrast-enhanced CT, PETCT, ultrasound, X-ray, and MRI, as well as endoscopic evaluations according to their group-specific schedules. These assessments occur from before treatment and continue at multiple time points up to five years after treatment. The study thus tracks disease markers, imaging findings, and methylation levels to understand treatment response and disease progression over a long-term period.
Actively Recruiting
Researchers are evaluating a new chemotherapy drug called JSKN003 in people with recurrent or metastatic breast cancer that is HER2-low and cannot be removed by surgery. This phase III clinical trial compares JSKN003 to chemotherapy drugs chosen by doctors in patients who have already tried and not responded to one or two previous chemotherapy treatments. The study aims to assess the safety and effectiveness of JSKN003 in this group of patients. Participants are randomly assigned to one of two groups one group receives JSKN003 alone given by intravenous infusion, while the other group receives one chemotherapy drug selected by their doctor from options like capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The choice of the chemotherapy drug for the control group is made before randomization. Treatment schedules follow the study protocol at multiple centers. During the study, participants will have regular assessments including scans to measure tumor progression and other tests to evaluate response and overall survival, monitored for up to about three years after enrollment. Researchers will track progression-free survival as the main outcome, along with overall survival, response rate, and duration of response. Safety and side effects will also be closely monitored throughout the study.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of combining orelabrutinib with the standard R-CHOP chemotherapy regimen as a first treatment for patients with CD5-positive diffuse large B-cell lymphoma DLBCL. This phase II, multicenter trial focuses on patients who have not received prior treatment. The study aims to understand if adding orelabrutinib improves patient outcomes compared to historical data. Participants will receive up to 8 cycles of treatment over several months. The first cycle uses R-CHOP alone, with orelabrutinib tablets 150 mg daily added starting from the second cycle. After 6 cycles of combination therapy, patients receive 2 more cycles of rituximab plus orelabrutinib. If a complete remission is achieved after these 8 cycles, patients will continue taking orelabrutinib as maintenance therapy. During the study, researchers will monitor participants closely with assessments to track disease progression, response to treatment, and side effects. They will measure outcomes such as event-free survival over 2 years, complete response rate, disease-free survival, and overall survival. Safety will be evaluated by recording adverse events throughout the study. The total participation period may last around 2 years, including follow-up to assess long-term effects.
1-10 of 11
1